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Sir,
Thank you for the opportunity to reply to the correspond-
ence concerning our recent publication in Brain,
‘Parkinson’s disease in GTP cyclohydrolase 1 mutation car-
riers’ (Mencacci et al., 2014). We read with great interest
these letters and we thank the authors for their insights.
Guella et al., 2014 report the screening of GCH1 in 528
Canadian cases with Parkinson’s disease and atypical par-
kinsonism and 290 matched controls. They identiﬁed two
variants, the known pathogenic p.K224R (2) and the
novel variant p.A99D (likely pathogenic according to in
silico prediction tools and interspecies conservation) in
three unrelated cases with Parkinsons’s disease and the
two benign variants p.P23L and p.P69L in one single con-
trol individual. The mutational frequency, excluding the
aforementioned benign variants, was 0.56% (3/528) in
cases versus 0% (0/290) in controls, consistent with the
frequency we observed in our study (0.75% in cases
versus 0.1% in controls).
This result is relevant as it represents the ﬁrst independ-
ent conﬁrmation that rare deleterious GCH1 variants are
enriched in patients with Parkinson’s disease compared to
control subjects. Furthermore, they describe the post-
mortem ﬁndings of one of the mutated patients, who pre-
sented at the age of 82 with DOPA-responsive asymmetric
rest tremor. This showed a combination of brainstem
Lewy body pathology together with the presence of tau-
immunoreactive neuroﬁbrillary tangles. To date, the only
available brain pathology analysis of a GCH1-associated
neurodegenerative parkinsonism case showed severe nigral
neurodegeneration and Lewy bodies in surviving nigral cells
and in the locus coeruleus (Gibb et al., 1991; Segawa et al.,
2004). Further studies are needed to establish if the tauo-
pathy described by Guella and colleagues in their case rep-
resents simply an incidental ﬁnding.
The ﬁnding that GCH1 loss-of-function variants are not
only responsible for childhood-onset DOPA-responsive dys-
tonia, but are also associated with adult-onset neurodegen-
erative parkinsonism, is strengthened by the recent
identiﬁcation, through the meta-analysis of genome-wide
association studies (GWAS) data deriving from 13 000
cases and 95 000 controls, that GCH1 is also a low-risk
susceptibility locus for Parkinson’s disease (Nalls et al.,
2014). This ﬁnding potentially extends the role of GTP
cyclohydrolase 1 (GCH1) deﬁciency in the pathogenesis
of Parkinson’s disease beyond carriers of rare deleterious
coding mutations.
The causal link between GCH1 and Parkinson’s disease
remains a matter of speculation. Ryan et al., 2014 ex-
pand the discussion of our manuscript and add insight
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into the possible pathogenic mechanisms that predispose
GCH1 loss-of-function mutation carriers to nigrostriatal
degeneration.
In our paper we proposed various hypotheses whereby
GCH1 and BH4 deﬁciency and consequent chronic reduc-
tion of dopamine levels may predispose carriers of GCH1
mutations to nigral cell degeneration.
Ryan and colleagues point out that different cellular
mechanisms secondary to BH4 deﬁciency, other than
reduced dopamine levels, could contribute to the death of
nigral dopaminergic neurons. BH4 acts as an antioxidant
itself and is an essential cofactor for nitric oxide synthases
(NOS) activity. Furthermore decreased BH4 levels have
been demonstrated to lead to NOS uncoupling, which re-
sults in increased oxidative and nitrative stress (Chen et al.,
2014). The authors previously described that a haplotype
of three SNPs (rs8007267, rs3783641 and rs10483639) at
the GCH1 genomic locus inﬂuences plasma GCH1 activity
and BH4 levels (Antoniades et al., 2008) and identiﬁed BH4
as a vascular defence mechanism against inﬂammation-
induced endothelial dysfunction (Antoniades et al., 2011).
Consequently the authors propose that a link between BH4
levels, oxidative stress, and neuroinﬂammation could rep-
resent the mechanism underlying GCH1-associated
Parkinson’s disease.
Fitting well with this model, and possibly supporting
Ryan et al.’s view, we found that the GCH1 SNP
(rs11158026), recently identiﬁed as a risk variant for
Parkinson’s disease (Nalls et al., 2014), is in moderate link-
age disequilibrium (r2 0.457; D’ 0.932) with the SNPs con-
stituting the functional haplotype. This possibly suggests a
potential functional basis for the association of this variant
to Parkinson’s disease.
The authors have also demonstrated the existence of an
interaction between -synuclein, mitochondrial function
and GCH1 activity. Their work may support the compel-
ling hypothesis that a pathogenic cascade occurs in nigral
neurons, whereby increased levels of -synuclein and mito-
chondrial dysfunction lead to decreased GCH1 activity and
BH4 levels, which in turn may result in increased oxidative
stress and cell death (Ryan et al., 2014).
We believe that one of the outstanding questions is
whether patients with DOPA-responsive dystonia eventu-
ally develop nigral neurodegeneration, or whether neurode-
generation can be avoided by dopaminergic replacement
therapy. Answering this question will help to understand
to what extent low dopamine levels play a role in nigral cell
death, with obvious therapeutic implications for asymptom-
atic carriers of pathogenic variants.
Dopaminergic imaging studies performed in a few cases
with classic DOPA-responsive dystonia (mostly genetically
not conﬁrmed) have shown no evidence of reduced nigros-
triatal innervation (Snow et al., 1993; Jeon et al., 1998).
This is consistent with post-mortem analysis of four extra
cases showing normal nigral cell count (Furukawa et al.,
1999; Grotzsch et al., 2002; Segawa et al., 2013).
However, Sawle and colleagues (1991) report that six
cases with DOPA-responsive dystonia displayed modest
but signiﬁcant reduction in the uptake of 18F-ﬂuorodopa
into both caudates and putamen. Furthermore, Tadic and
colleagues (2012) report that in DOPA-responsive dystonia
cases parkinsonian signs are a relatively common residual
motor sign following treatment, possibly suggesting under-
lying neurodegeneration.
With regards to this, the case report of Terbeek et al.,
2014 is of great interest. They describe a 41-year-old pa-
tient carrying a known pathogenic GCH1 variant (p.Y75S)
with onset of classic DOPA-responsive dystonia at age 11.
He was treated with L-DOPA (300mg/day) from the age of
20 with good and sustained response. At age 41, because of
rapid recurrence of dystonia after skipping a L-DOPA dose,
dopaminergic imaging (123I-FP-CIT SPECT) was performed
and showed severe bilateral and asymmetric reduction of
putaminal tracer uptake, a pattern typical of idiopathic
Parkinson’s disease. However, clinical examination, per-
formed after withdrawing L-DOPA, revealed purely dys-
tonic features without any obvious sign of parkinsonism.
In agreement with the interpretation of Terbeek and col-
leagues, we believe that this case may indeed represent a
case with overlapping DOPA-responsive dystonia and
asymptomatic, as yet, nigrostriatal degeneration, possibly
arguing against a neuroprotective role of dopamine replace-
ment in GCH1 mutation carriers.
Lastly, with regards to the letter by Furukawa and Kish
(2014), we agree it is not easy to reconcile the evidence of
nigral neurodegeneration that we and others have demon-
strated in several individuals with GCH1-related parkinson-
sim and the intact dopaminergic innervation showed in
some other cases (Nygaard et al., 1992; Kang et al., 2004).
However, the phenotype of these latter cases, character-
ized by excellent and prolonged response to very small
doses of L-DOPA and no motor ﬂuctuations or dyskinesias
in spite of decades of treatment, is very different from what
we observed in the ‘neurodegenerative’ cases. It is therefore
possible that there may exist two different types of adult-
onset parkinsonism associated with GCH1 mutations; on
one side, a benign non-degenerative form, part of the
phenotypic spectrum of metabolic GCH1-related striatal
dopamine deﬁciency; on the other, a progressive form of
parkinsonism with underlying nigral degeneration.
In conclusion, we anticipate that post-mortem analysis
and longitudinal clinical, neuroimaging, and metabolic stu-
dies of larger series of GCH1 mutation carriers—including
asymptomatic carriers, individuals with classic DOPA-
responsive dystonia and cases with adult-onset parkinson-
ism—will give way to important understandings of the
pathogenesis of GCH1–associated Parkinson’s disease.
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